Stock Events

Stock Events

Phathom Pharmaceuticals 

$9.50
33
+$0.45+4.97% Friday 20:00
-$0.12-1.26%Friday 23:35After hours

Statistics

Day High
9.09
Day Low
8.95
52W High
18.31
52W Low
8.21
Volume
930
Avg. Volume
-
Mkt Cap
768.56M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.31
-0.89
-0.48
-0.06
Expected EPS
-0.0637
Actual EPS
N/A

Financials

-126.35%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
175.11MRevenue
-221.25MNet Income

Analyst Ratings

21.00Average Price Target
The highest estimate is 26.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow PHAT. It's not an investment recommendation.
AMD
10
AMD
NVIDIA
8
NVDA
Apple
7
AAPL
Amazon
7
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Takeda Pharmaceutical
TAK
Mkt Cap57.58B
Takeda Pharmaceutical Company has a strong portfolio in gastroenterology, competing in the same space as Phathom Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca produces gastrointestinal drugs that directly compete with Phathom's offerings.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie, having acquired Allergan, competes in the gastrointestinal drug market, overlapping with Phathom's therapeutic areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products that compete in the gastrointestinal sector.
Sanofi
SNY
Mkt Cap107.39B
Sanofi has a presence in the gastroenterology market, making it a competitor to Phathom Pharmaceuticals.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a diverse range of products, including treatments for gastrointestinal disorders, competing with Phathom.
Novartis
NVS
Mkt Cap292.35B
Novartis offers medications for a variety of conditions, including gastrointestinal diseases, competing with Phathom Pharmaceuticals.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. provides therapeutic solutions in various areas, including gastroenterology, making it a competitor.
GSK
GSK
Mkt Cap101.78B
GlaxoSmithKline has a portfolio of medicines that includes treatments for acid-related conditions, competing with Phathom Pharmaceuticals.

About

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
Show more...
CEO
Steven L. Basta
Employees
371
Country
United States
ISIN
US71722W1071

Listings

XNAS
US
PHAT
BOATS
BOATS
PHAT.BOATS

0 Comments

Share your thoughts

FAQ

What is Phathom Pharmaceuticals stock price today?▼
The current price of PHAT is $9.50 USD — it has increased by +4.97% in the past 24 hours. Watch Phathom Pharmaceuticals stock price performance more closely on the chart.
What is Phathom Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Phathom Pharmaceuticals stocks are traded under the ticker PHAT.
Is Phathom Pharmaceuticals stock price growing?▼
PHAT stock has risen by +3.49% compared to the previous week, the month change is a +15.43% rise, over the last year Phathom Pharmaceuticals has showed a -23.01% decrease.
What is Phathom Pharmaceuticals market cap?▼
Today Phathom Pharmaceuticals has the market capitalization of 768.56M
When is the next Phathom Pharmaceuticals earnings date?▼
Phathom Pharmaceuticals is going to release the next earnings report on November 05, 2026.
What were Phathom Pharmaceuticals earnings last quarter?▼
PHAT earnings for the last quarter are -0.21 USD per share, whereas the estimation was -0.18 USD resulting in a -19.6% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Phathom Pharmaceuticals revenue for the last year?▼
Phathom Pharmaceuticals revenue for the last year amounts to 175.11M USD.
What is Phathom Pharmaceuticals net income for the last year?▼
PHAT net income for the last year is -221.25M USD.
How many employees does Phathom Pharmaceuticals have?▼
As of September 05, 2026, the company has 371 employees.
In which sector is Phathom Pharmaceuticals located?▼
Phathom Pharmaceuticals operates in the Health & Wellness sector.
When did Phathom Pharmaceuticals complete a stock split?▼
Phathom Pharmaceuticals has not had any recent stock splits.
Where is Phathom Pharmaceuticals headquartered?▼
Phathom Pharmaceuticals is headquartered in FLORHAM PARK, United States.